Advanced search
Publication Cover
Pharmacogenomics Volume 15, 2014 - Issue 5
Submit an article Journal homepage
252
Views
0
CrossRef citations to date
0
Altmetric
Perspective

Comparative Pharmacogenetics of Multiple Sclerosis: IFN-β Versus Glatiramer Acetate

Olga G Kulakova1 Pirogov Russian National Research Medical University, Ostrovitianov str. 1, 117997, Moscow, RussiaCorrespondence[email protected]
View further author information
,
Ekaterina Yu Tsareva1 Pirogov Russian National Research Medical University, Ostrovitianov str. 1, 117997, Moscow, RussiaView further author information
,
Dmitrijs Lvovs2 State Research Institute for Genetics & Selection of Industrial Microorganisms, 1-st Dorozhniy pr., 1, 117545Moscow, RussiaView further author information
,
Alexander V Favorov3 Vavilov Institute of General Genetics, Gubkin str. 3, 119333, Moscow, Russia; Research Institute for Genetics & Selection of Industrial Microorganisms, 1-st Dorozhniy pr., 1, 117545Moscow, Russia;4 Johns Hopkins University School of Medicine, 4940 Eastern Avenue, Baltimore, MD, 21224, USAView further author information
,
Alexey N Boyko5 City Hospital #11 of Moscow Health Care Department & Moscow MS Center, Pirogov Russian National Research Medical University, Ostrovitianov str. 1, 117997, Moscow, oRussiaView further author information
&
Olga O Favorova1 Pirogov Russian National Research Medical University, Ostrovitianov str. 1, 117997, Moscow, RussiaView further author information
Pages 679-685 | Published online: 05 May 2014

References

  • Rudick RA , GoelzSE. Beta-interferon for multiple sclerosis. Exp. Cell Res.317(9) , 1301–1311 (2011).
  • Johnson KP . Glatiramer acetate for treatment of relapsing–remitting multiple sclerosis. Expert Rev. Neurother.12(4) , 371–384 (2012).
  • Schreiber K , VoldsgaardA, SorensenPS. Limited effect of interferon-beta for the treatment of secondary progressive multiple sclerosis. Ugeskr. Laeger175(19) , 1342–1344 (2013).
  • Saidha S , EcksteinC, CalabresiPA. New and emerging disease modifying therapies for multiple sclerosis. Ann. NY Acad. Sci.1247 , 117–137 (2012).
  • Mendes A , SaMJ. Classical immunomodulatory therapy in multiple sclerosis: how it acts, how it works. Arq. Neuropsiquiatr.69(3) , 536–543 (2011).
  • Comi G , FilippiM, WolinskyJS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann. Neurol.49(3) , 290–297 (2001).
  • Rio J , NosC, TintoreM et al. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann. Neurol. 59(2) , 344–352 (2006).
  • Gajofatto A , BacchettiP, GrimesB, HighA, WaubantE. Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis. Mult. Scler.15(1) , 50–58 (2009).
  • Foti C uzzola V, Palella E, Celi D et al. Pharmacogenomic update on multiple sclerosis: a focus on actual and new therapeutic strategies. Pharmacogenomics J.12(6) , 453–461 (2012).
  • Vandenbroeck K , ComabellaM. Single-nucleotide polymorphisms in response to interferon-beta therapy in multiple sclerosis. J. Interferon Cytokine Res.30(10) , 727–732 (2010).
  • Byun E , CaillierSJ, MontalbanX et al. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. Arch. Neurol. 65(3) , 337–344 (2008).
  • Comabella M , CraigDW, Morcillo-SuarezC et al. Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis. Arch. Neurol. 66(8) , 972–978 (2009).
  • Mahurkar S , SuppiahV, O‘DohertyC. Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature. Autoimmun. Rev.13(2) , 178–186 (2014).
  • Goertsches RH , ZettlUK, HeckerM. Sieving treatment biomarkers from blood gene-expression profiles: a pharmacogenomic update on two types of multiple sclerosis therapy. Pharmacogenomics12(3) , 423–432 (2011).
  • O‘Doherty C , FavorovA, HeggartyS et al. Genetic polymorphisms, their allele combinations and IFN-beta treatment response in Irish multiple sclerosis patients. Pharmacogenomics 10(7) , 1177–1186 (2009).
  • Kulakova OG , TsarevaEY, BoykoAN et al. Allelic combinations of immune-response genes as possible composite markers of IFN-beta efficacy in multiple sclerosis patients. Pharmacogenomics 13(15) , 1689–1700 (2012).
  • Tsareva EY , KulakovaOG, BoykoAN et al. Allelic combinations of immune-response genes associated with glatiramer acetate treatment response in Russian multiple sclerosis patients. Pharmacogenomics 13(1) , 43–53 (2012).
  • Tsareva E , KulakovaOG, MakarychevaO et al. Pharmacogenomics of multiple sclerosis: association of immune response genes polymorphism with copaxone treatment efficacy. Mol. Biol. (Mosk) 45(6) , 963–972 (2011).
  • Polman CH , ReingoldSC, EdanG et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann. Neurol. 58(6) , 840–846 (2005).
  • APSampler software for complex association analysis of genotypic and phenotypic data. https://code.google.com/p/apsampler
  • Favorov AV , AndreewskiTV, SudomoinaMA, FavorovaOO, ParmigianiG, OchsMF. A Markov chain Monte Carlo technique for identification of combinations of allelic variants underlying complex diseases in humans. Genetics171(4) , 2113–2121 (2005).
  • Kieseier BC . The mechanism of action of interferon-beta in relapsing multiple sclerosis. CNS Drugs25(6) , 491–502 (2011).
  • Lalive PH , NeuhausO, BenkhouchaM et al. Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action. CNS Drugs 25(5) , 401–414 (2011).
  • He XX , ChangY, JiangHJ et al. Persistent effect of IFNAR-1 genetic polymorphism on the long-term pathogenesis of chronic HBV infection. Viral Immunol. 23(3) , 251–257 (2010).
  • Sudomoina MA , BoikoAN, DeminaTL et al. Connection of multiple sclerosis in the Russian population with alleles of the major histocompatibility complex DRB1 gene. Mol. Biol. (Mosk) 32(2) , 291–296 (1998).
  • Ligers A , TeleshovaN, MastermanT, HuangWX, HillertJ. CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms. Genes Immun.2(3) , 145–152 (2001).
  • Sato K , KawasakiH, NagayamaH et al. TGF-beta 1 reciprocally controls chemotaxis of human peripheral blood monocyte-derived dendritic cells via chemokine receptors. J. Immunol. 164(5) , 2285–2295 (2000).
  • dbSNP : the NCBI curated database of SNPs and other small-scale variants. www.ncbi.nlm.nih.gov/snp
  • NHS curated database of the worldwide allele frequencies. www.allelefrequencies.net

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.